Theravance's telavancin, an investigational antibiotic for complex skin infections, may cause birth defects when taken by pregnant women or trigger complications in patients with kidney failure, according to a preliminary analysis from the FDA. The company said the injectable drug shows promise in combating microbes resistant to antibiotics on the market. A panel of FDA experts plans to meet Wednesday to discuss telavancin's safety and efficacy.

Full Story:
Reuters, Google

Related Summaries